3.9400 +0.04 (1.03%)
After hours: 6:53PM EST
|Bid||3.9900 x 3200|
|Ask||3.9800 x 3000|
|Day's Range||3.8000 - 4.4200|
|52 Week Range||0.2310 - 5.7500|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 31, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
Genprex, Inc. Prices $17,500,000 Common Stock Offering Priced At-The-Market and Without Warrants
Benzinga Pro's Stocks To Watch For Wednesday Bellerophon (BLPH) - Following a nearly 170% rally to close Tuesday's session, Bellerophon shares pulled back about 5% to under the $9 level Wednesday morning. ...
Genprex licenses patented diabetes gene therapy from University of Pittsburgh.
Genprex provides a clinical update on its planned clinical trials moving forward.
While adding money to the balance sheet is seldom a negative, the impact it can have on shareholders or the stock price can absolutely create a negative overhang sometimes lasting for months, if not longer. It's easy to find examples of a "bad" capital raise as well as a good capital raise, but it is seldom you see both from the same company within a two month span, but that's exactly what we got with Genprex .
Shares of Genprex Inc. climbed 53% in morning trading on Wednesday after the company said the Food and Drug Administration had granted its experimental cancer treatment a fast-track designation. Genprex is testing the therapy in combination with AstraZeneca's Tagrisso for certain non-small cell lung cancer patients. AstraZeneca said in October that Tagrisso brought in $2.3 billion in sales year-to-date, an 82% jump compared to the year prior. Its stock was up 0.7% on Wednesday. Genprex plans to start a Phase I/II clinical trial for the investigational combination treatment. Genprex's stock is up 12% over the past year, while the S&P 500 has gained 24%.
AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16 th , 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, ...
Treatment for breast cancer varies, based on both the patient’s circumstances and type of cancer. The development of treatments to suppress or even eliminate cancer has led to a high survival rate in wealthy countries, with around 85% of patients in the United States and United Kingdom surviving for at least five years from diagnosis. Cancer is a difficult disease to defeat, and survival can depend upon the ability of scientists to counter a specific genetic defect in a specific set of cells.
NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Genprex Inc. (GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. Advances in biotechnology look to deliver promising new treatment options against breast cancer. Breast cancer is one of the most widely prevalent cancers in the world.
Imagined in the 1970s and first carried out in the 1980s, gene therapy is one of the newest frontiers in medicine. A number of companies have emerged with the aim of applying gene therapy to specific diseases. For example, Genprex Inc. (GNPX) specializes in tackling non-small cell lung cancer through its developmental drug Oncoprex(TM).